On May 22, 2020, Qualigen Therapeutics, Inc., formerly known as Ritter Pharmaceuticals, Inc. (the Company), completed its previously announced reverse merger transaction with Qualigen, Inc. (Qualigen – not to be confused with the Company) in accordance with the terms of the Agreement and Plan of Merger, dated as of January 15, 2020, by and among the Company, RPG28 Merger Sub, Inc. (Merger Sub), and Qualigen (as amended on February 1, 2020 and March 26, 2020, the Merger Agreement), pursuant to which Merger Sub merged with and into Qualigen with Qualigen surviving as a wholly owned subsidiary of the Company (the Merger). The former stockholders of Qualigen acquired, via the merger, a substantial majority of the shares of the Company. In accordance with the Merger Agreement, and effective upon the closing of the Merger, Andrew Ritter, Noah Doyle, Matthew Foehr, Paul Maier and William Merino resigned from the Company’s board of directors. In addition, in accordance with the Merger Agreement, and effective upon the closing of the Merger, all of the Company’s officers (Andrew Ritter, Ira Ritter and John Beck) resigned from their officer and employee positions. These director and officer resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. In accordance with the Merger Agreement, the Company’s board of directors was reconstituted to include the following directors as of May 22, 2020: Michael S. Poirier as Chairman, Kurt H. Kruger as Director, Richard A. David, MD FACS as Director, Matthew E. Korenberg as Director and Ira E. Ritter as Director.